vs
AVANOS MEDICAL, INC.(AVNS)とMSA Safety Inc(MSA)の財務データ比較。上の社名をクリックして会社を切り替えられます
MSA Safety Incの直近四半期売上が大きい($510.9M vs $180.9M、AVANOS MEDICAL, INC.の約2.8倍)。MSA Safety Incの純利益率が高く(17.0% vs -0.7%、差は17.7%)。MSA Safety Incの前年同期比売上増加率が高い(2.2% vs 0.7%)。MSA Safety Incの直近四半期フリーキャッシュフローが多い($106.0M vs $21.3M)。過去8四半期でMSA Safety Incの売上複合成長率が高い(11.2% vs 4.4%)
Avanos Medicalは医療テクノロジー企業で、臨床医療機器の開発・製造に注力しており、疼痛管理と慢性ケアの2つのコア事業を展開しています。患者の回復促進や感染予防に取り組みながら、治療におけるオピオイド系薬剤の使用削減を目指しています。
MSAセーフティ(別名マイン・セーフティ・アプライアンシズ)は米国の安全機器メーカー兼サプライヤーで、建設、軍事、消防、化学、石油・ガス生産など危険を伴う業界向けに製品を供給し、本社はピッツバーグ郊外のクランベリーに所在しています。
AVNS vs MSA — 直接比較
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | ||
|---|---|---|
| 売上 | $180.9M | $510.9M |
| 純利益 | $-1.3M | $86.9M |
| 粗利率 | 47.5% | 46.9% |
| 営業利益率 | 1.4% | 22.3% |
| 純利益率 | -0.7% | 17.0% |
| 売上前年比 | 0.7% | 2.2% |
| 純利益前年比 | 99.7% | -1.2% |
| EPS(希薄化後) | $-0.02 | $2.22 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $180.9M | $510.9M | ||
| Q3 25 | $177.8M | $468.4M | ||
| Q2 25 | $175.0M | $474.1M | ||
| Q1 25 | $167.5M | $421.3M | ||
| Q4 24 | $179.6M | $499.7M | ||
| Q3 24 | $170.4M | $432.7M | ||
| Q2 24 | $171.7M | $462.5M | ||
| Q1 24 | $166.1M | $413.3M |
| Q4 25 | $-1.3M | $86.9M | ||
| Q3 25 | $-1.4M | $69.6M | ||
| Q2 25 | $-76.8M | $62.8M | ||
| Q1 25 | $6.6M | $59.6M | ||
| Q4 24 | $-397.3M | $87.9M | ||
| Q3 24 | $4.3M | $66.6M | ||
| Q2 24 | $1.8M | $72.2M | ||
| Q1 24 | $-900.0K | $58.1M |
| Q4 25 | 47.5% | 46.9% | ||
| Q3 25 | 48.4% | 46.5% | ||
| Q2 25 | 52.6% | 46.6% | ||
| Q1 25 | 53.6% | 45.9% | ||
| Q4 24 | 54.6% | 46.9% | ||
| Q3 24 | 54.5% | 47.9% | ||
| Q2 24 | 55.7% | 48.2% | ||
| Q1 24 | 57.1% | 47.3% |
| Q4 25 | 1.4% | 22.3% | ||
| Q3 25 | 0.1% | 20.1% | ||
| Q2 25 | -42.6% | 18.1% | ||
| Q1 25 | 6.1% | 18.5% | ||
| Q4 24 | -233.0% | 23.5% | ||
| Q3 24 | 7.0% | 21.1% | ||
| Q2 24 | 3.7% | 21.6% | ||
| Q1 24 | 2.4% | 19.4% |
| Q4 25 | -0.7% | 17.0% | ||
| Q3 25 | -0.8% | 14.9% | ||
| Q2 25 | -43.9% | 13.2% | ||
| Q1 25 | 3.9% | 14.1% | ||
| Q4 24 | -221.2% | 17.6% | ||
| Q3 24 | 2.5% | 15.4% | ||
| Q2 24 | 1.0% | 15.6% | ||
| Q1 24 | -0.5% | 14.1% |
| Q4 25 | $-0.02 | $2.22 | ||
| Q3 25 | $-0.03 | $1.77 | ||
| Q2 25 | $-1.66 | $1.59 | ||
| Q1 25 | $0.14 | $1.51 | ||
| Q4 24 | $-8.64 | $2.22 | ||
| Q3 24 | $0.09 | $1.69 | ||
| Q2 24 | $0.04 | $1.83 | ||
| Q1 24 | $-0.02 | $1.47 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $89.8M | $165.1M |
| 総負債低いほど良い | $90.3M | $580.9M |
| 株主資本純資産 | $778.2M | $1.4B |
| 総資産 | $1.1B | $2.6B |
| 負債/資本比率低いほどレバレッジが低い | 0.12× | 0.42× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $89.8M | $165.1M | ||
| Q3 25 | $70.5M | $170.0M | ||
| Q2 25 | $90.3M | $147.0M | ||
| Q1 25 | $97.0M | $170.6M | ||
| Q4 24 | $107.7M | $164.6M | ||
| Q3 24 | $89.0M | $154.4M | ||
| Q2 24 | $92.2M | $146.8M | ||
| Q1 24 | $75.8M | $148.3M |
| Q4 25 | $90.3M | $580.9M | ||
| Q3 25 | $93.4M | $628.6M | ||
| Q2 25 | $95.7M | $679.3M | ||
| Q1 25 | $98.0M | $502.1M | ||
| Q4 24 | $125.3M | $508.0M | ||
| Q3 24 | $152.6M | $554.7M | ||
| Q2 24 | $164.9M | $588.2M | ||
| Q1 24 | $167.2M | $596.2M |
| Q4 25 | $778.2M | $1.4B | ||
| Q3 25 | $778.0M | $1.3B | ||
| Q2 25 | $776.3M | $1.3B | ||
| Q1 25 | $839.4M | $1.2B | ||
| Q4 24 | $828.5M | $1.1B | ||
| Q3 24 | $1.2B | $1.1B | ||
| Q2 24 | $1.2B | $1.0B | ||
| Q1 24 | $1.2B | $994.8M |
| Q4 25 | $1.1B | $2.6B | ||
| Q3 25 | $1.1B | $2.6B | ||
| Q2 25 | $1.0B | $2.6B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.2B | $2.2B | ||
| Q3 24 | $1.7B | $2.2B | ||
| Q2 24 | $1.7B | $2.2B | ||
| Q1 24 | $1.7B | $2.2B |
| Q4 25 | 0.12× | 0.42× | ||
| Q3 25 | 0.12× | 0.48× | ||
| Q2 25 | 0.12× | 0.54× | ||
| Q1 25 | 0.12× | 0.42× | ||
| Q4 24 | 0.15× | 0.44× | ||
| Q3 24 | 0.12× | 0.51× | ||
| Q2 24 | 0.13× | 0.57× | ||
| Q1 24 | 0.14× | 0.60× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $28.2M | $122.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $21.3M | $106.0M |
| FCFマージンFCF / 売上 | 11.8% | 20.8% |
| 設備投資強度設備投資 / 売上 | 3.8% | 3.2% |
| キャッシュ転換率営業CF / 純利益 | — | 1.41× |
| 直近12ヶ月FCF直近4四半期 | $43.1M | $295.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $28.2M | $122.4M | ||
| Q3 25 | $14.0M | $112.5M | ||
| Q2 25 | $6.8M | $67.2M | ||
| Q1 25 | $25.7M | $61.8M | ||
| Q4 24 | $57.9M | $107.9M | ||
| Q3 24 | $23.0M | $84.3M | ||
| Q2 24 | $27.8M | $53.3M | ||
| Q1 24 | $-8.0M | $50.9M |
| Q4 25 | $21.3M | $106.0M | ||
| Q3 25 | $7.0M | $100.5M | ||
| Q2 25 | $-4.2M | $37.9M | ||
| Q1 25 | $19.0M | $51.0M | ||
| Q4 24 | $53.1M | $93.5M | ||
| Q3 24 | $20.0M | $70.1M | ||
| Q2 24 | $21.9M | $39.0M | ||
| Q1 24 | $-12.1M | $39.7M |
| Q4 25 | 11.8% | 20.8% | ||
| Q3 25 | 3.9% | 21.4% | ||
| Q2 25 | -2.4% | 8.0% | ||
| Q1 25 | 11.3% | 12.1% | ||
| Q4 24 | 29.6% | 18.7% | ||
| Q3 24 | 11.7% | 16.2% | ||
| Q2 24 | 12.8% | 8.4% | ||
| Q1 24 | -7.3% | 9.6% |
| Q4 25 | 3.8% | 3.2% | ||
| Q3 25 | 3.9% | 2.6% | ||
| Q2 25 | 6.3% | 6.2% | ||
| Q1 25 | 4.0% | 2.6% | ||
| Q4 24 | 2.7% | 2.9% | ||
| Q3 24 | 1.8% | 3.3% | ||
| Q2 24 | 3.4% | 3.1% | ||
| Q1 24 | 2.5% | 2.7% |
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.62× | ||
| Q2 25 | — | 1.07× | ||
| Q1 25 | 3.89× | 1.04× | ||
| Q4 24 | — | 1.23× | ||
| Q3 24 | 5.35× | 1.27× | ||
| Q2 24 | 15.44× | 0.74× | ||
| Q1 24 | — | 0.88× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
MSA
| Americas Segment | $335.2M | 66% |
| International Segment | $175.7M | 34% |